PJA1 and nasopharyngeal carcinoma: Taken together, these findings indicate that pharmacological targeting of PJA1 with RTA402 enhances docetaxel-induced antitumour immunity and docetaxel sensitivity and that the combination of small molecular inhibitor RTA402 and docetaxel is an effective therapy for NPC.